By Daniella Parra
Radiant Biotherapeutics presented data from their advancing a breakthrough antibody approach, the Multabody which uniquely harnesses natural mechanisms to effectively engage multiple disease targets with unmatched strength, precise tunability, and exceptional breadth, they said.
They said RBT-101 achieved sustained complete tumor regression in MC38 colorectal mouse tumor model and demonstrated no signs of liver toxicity.
“Our data to be presented at SITC demonstrates that RBT-101 achieves what first-generation 4-1BB agonists could not – delivering robust anti-tumor activity without liver toxicity,” said Jo Hulme, Ph.D., CSO of Radiant. “This validates our Multabody platform’s potential to address a broad range of therapeutic targets while avoiding the inherent limitations of conventional antibody-based approaches, as RBT-101 drove potent, tunable and safe agonism of 4-1BB that more closely mimicked natural ligand biology. We look forward to the continued development of Multabodies as promising therapeutics in oncology and other disease areas.”
READ MORE
Never Miss our Weekly Highlights HERE
